Alexion Pharmaceuticals, Inc. (ALXN) CFO Paul J. Clancy Sells 6,079 Shares

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) CFO Paul J. Clancy sold 6,079 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $707,048.49. Following the completion of the transaction, the chief financial officer now directly owns 95,093 shares in the company, valued at $11,060,266.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down $8.68 on Thursday, hitting $108.47. 3,723,831 shares of the stock were exchanged, compared to its average volume of 2,054,928. The stock has a market capitalization of $25,400.00, a price-to-earnings ratio of 48.42, a PEG ratio of 0.96 and a beta of 1.16. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.21. The firm had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 earnings per share. equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Ameriprise Financial Inc. boosted its holdings in Alexion Pharmaceuticals by 3.5% in the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after purchasing an additional 215,005 shares during the last quarter. Jennison Associates LLC boosted its holdings in Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Alexion Pharmaceuticals by 32.7% in the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after purchasing an additional 383,713 shares during the last quarter. Bank of Montreal Can boosted its holdings in Alexion Pharmaceuticals by 21.4% in the fourth quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock valued at $181,998,000 after purchasing an additional 268,053 shares during the last quarter. Finally, Temasek Holdings Private Ltd boosted its holdings in Alexion Pharmaceuticals by 3.6% in the third quarter. Temasek Holdings Private Ltd now owns 1,505,325 shares of the biopharmaceutical company’s stock valued at $211,182,000 after purchasing an additional 52,403 shares during the last quarter. 94.04% of the stock is currently owned by institutional investors.

Several equities analysts have issued reports on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. Royal Bank of Canada lifted their price target on shares of Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Stifel Nicolaus cut their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a report on Tuesday, October 31st. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 price target (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $153.10.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) CFO Paul J. Clancy Sells 6,079 Shares” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2018/02/08/alexion-pharmaceuticals-inc-alxn-cfo-paul-j-clancy-sells-6079-shares.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit